On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Q2 2025 Management View CEO Leonard S. Schleifer reported "Regeneron delivered a strong second quarter, driven by durable ...

Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron ...

On July 2, the US FDA) granted accelerate approval to Regeneron Pharmaceuticals’s linvoseltamab-gcpt, which is marketed under the brand name Lynozyfic.

Regeneron announced FDA accelerated approval for Lynozyfic™ to treat advanced multiple myeloma in heavily pre-treated patients. Quiver AI Summary Regeneron Pharmaceuticals announced that the FDA ...

Regeneron on Wednesday said the FDA green light covers Lynozyfic in adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a ...

Q2 2025 Earnings Call Transcript August 1, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

--Regeneron Pharmaceuticals, Inc. today announced that the European Commission has granted conditional marketing approval of Lynozyfic™ to treat adults with relapsed and refractory multiple myeloma.